SCHEMBL1875288

SCHEMBL1875288

Cc1ccc(C)n1-c1nccc(-c2c(-c3ccc(F)cc3)noc2N)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.58
MAPK9 P45984 2/20 0.58
MAPK10 P53779 2/20 0.58
MAPK11 Q15759 2/20 0.58
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
GLA P06280 2/20 0.43
GAA P10253 2/20 0.43
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 1/20 0.39
LMNA P02545 1/20 0.39
PTGS2 P35354 4/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CSNK1D P48730 2/20 0.37
MAPK13 O15264 1/20 0.35
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4330136 0.78 MAPK14 (0.57) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1874114 0.78 MAPK14 (0.62) MAPK14MAPK9MAPK10MAPK11KDM4E
SCHEMBL1877377 0.74 MAPK14 (1.00) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL4333428 0.72 MAPK14 (0.66) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL4334939 0.70 MAPK14 (0.62) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1875864 0.69 MAPK14 (0.66) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1881013 0.69 MAPK14 (0.54) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL4329223 0.69 MAPK14 (0.69) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL14626838 0.69 POLB (0.53) MAPK14MAPK9MAPK10MAPK11MAPT
SCHEMBL6102776 0.68 MAPK14 (1.00) MAPK14MAPK9MAPK10MAPK11CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 MAPK14 29/4885MAPK9 20/4885MAPK10 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.